Robert E. Strecker, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sleep Deprivation | 29 | 2023 | 846 | 4.140 |
Why?
|
| Wakefulness | 24 | 2022 | 1265 | 1.320 |
Why?
|
| Prosencephalon | 11 | 2012 | 305 | 1.270 |
Why?
|
| Sleep | 26 | 2021 | 4768 | 1.120 |
Why?
|
| Parvalbumins | 6 | 2023 | 261 | 1.120 |
Why?
|
| Attention | 8 | 2023 | 2396 | 1.060 |
Why?
|
| Adenosine | 11 | 2018 | 808 | 0.810 |
Why?
|
| Sleep Stages | 8 | 2020 | 694 | 0.790 |
Why?
|
| Maze Learning | 5 | 2013 | 483 | 0.770 |
Why?
|
| Microdialysis | 18 | 2008 | 161 | 0.690 |
Why?
|
| Rats | 55 | 2021 | 23741 | 0.670 |
Why?
|
| Arousal | 8 | 2022 | 1166 | 0.640 |
Why?
|
| Dopamine | 19 | 1998 | 1607 | 0.620 |
Why?
|
| Rodentia | 3 | 2020 | 262 | 0.610 |
Why?
|
| Neurons | 22 | 2023 | 9463 | 0.590 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2020 | 1081 | 0.580 |
Why?
|
| Sleep, REM | 15 | 2020 | 595 | 0.560 |
Why?
|
| Nucleus Accumbens | 8 | 2005 | 366 | 0.540 |
Why?
|
| Receptors, Purinergic P1 | 3 | 2015 | 108 | 0.530 |
Why?
|
| Disorders of Excessive Somnolence | 2 | 2008 | 277 | 0.480 |
Why?
|
| Rats, Sprague-Dawley | 23 | 2018 | 8181 | 0.460 |
Why?
|
| Reaction Time | 7 | 2023 | 2089 | 0.450 |
Why?
|
| Memory Disorders | 2 | 2013 | 1199 | 0.450 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2013 | 52 | 0.440 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2013 | 43 | 0.440 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2013 | 69 | 0.440 |
Why?
|
| Norepinephrine | 4 | 2022 | 897 | 0.430 |
Why?
|
| Polysomnography | 8 | 2019 | 1848 | 0.420 |
Why?
|
| Allostasis | 1 | 2013 | 72 | 0.410 |
Why?
|
| Preoptic Area | 4 | 2002 | 132 | 0.410 |
Why?
|
| Brain Chemistry | 3 | 2007 | 960 | 0.410 |
Why?
|
| Memory | 6 | 2019 | 2193 | 0.410 |
Why?
|
| Psychomotor Performance | 4 | 2008 | 1882 | 0.400 |
Why?
|
| Rats, Inbred F344 | 6 | 2010 | 826 | 0.400 |
Why?
|
| Anterior Hypothalamic Nucleus | 2 | 2002 | 4 | 0.390 |
Why?
|
| Indenes | 1 | 2012 | 59 | 0.380 |
Why?
|
| Corticosterone | 3 | 2008 | 305 | 0.370 |
Why?
|
| Motor Activity | 16 | 2010 | 2715 | 0.360 |
Why?
|
| Electroencephalography | 19 | 2020 | 6237 | 0.360 |
Why?
|
| Thirst | 1 | 2010 | 42 | 0.350 |
Why?
|
| Animals | 89 | 2023 | 168475 | 0.350 |
Why?
|
| Choline O-Acetyltransferase | 3 | 2009 | 156 | 0.340 |
Why?
|
| Escape Reaction | 1 | 2009 | 57 | 0.330 |
Why?
|
| Behavior, Animal | 11 | 2017 | 1878 | 0.320 |
Why?
|
| Drinking | 1 | 2010 | 198 | 0.320 |
Why?
|
| Exploratory Behavior | 2 | 2008 | 279 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2012 | 3980 | 0.310 |
Why?
|
| Serotonin | 11 | 2006 | 1041 | 0.310 |
Why?
|
| Orientation | 1 | 2009 | 321 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2009 | 586 | 0.280 |
Why?
|
| Spatial Behavior | 2 | 2006 | 88 | 0.280 |
Why?
|
| Mental Recall | 1 | 2013 | 1221 | 0.270 |
Why?
|
| Extracellular Space | 7 | 2002 | 563 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2019 | 174 | 0.270 |
Why?
|
| Brain Waves | 3 | 2019 | 409 | 0.260 |
Why?
|
| Space Perception | 1 | 2009 | 465 | 0.260 |
Why?
|
| Memory, Short-Term | 2 | 2010 | 982 | 0.260 |
Why?
|
| Receptor, Adenosine A1 | 4 | 2012 | 42 | 0.260 |
Why?
|
| Cats | 17 | 2004 | 975 | 0.250 |
Why?
|
| Discrimination Learning | 1 | 2007 | 278 | 0.240 |
Why?
|
| Psychomotor Disorders | 1 | 2006 | 149 | 0.240 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 293 | 0.230 |
Why?
|
| Histamine | 2 | 2004 | 499 | 0.220 |
Why?
|
| Rats, Inbred Strains | 14 | 2010 | 2088 | 0.220 |
Why?
|
| Reward | 1 | 2010 | 971 | 0.210 |
Why?
|
| Rats, Long-Evans | 4 | 2013 | 383 | 0.210 |
Why?
|
| Raphe Nuclei | 8 | 2006 | 103 | 0.210 |
Why?
|
| Motivation | 2 | 2010 | 2006 | 0.210 |
Why?
|
| Brain | 12 | 2020 | 27121 | 0.210 |
Why?
|
| Substantia Nigra | 7 | 1993 | 350 | 0.210 |
Why?
|
| Hippocampus | 6 | 2006 | 3766 | 0.210 |
Why?
|
| Electromyography | 8 | 2008 | 1394 | 0.210 |
Why?
|
| Delta Rhythm | 2 | 2020 | 81 | 0.200 |
Why?
|
| Time Factors | 15 | 2015 | 39969 | 0.190 |
Why?
|
| Locus Coeruleus | 2 | 2022 | 230 | 0.190 |
Why?
|
| Executive Function | 1 | 2010 | 1392 | 0.190 |
Why?
|
| Schizophrenia | 4 | 2020 | 6937 | 0.180 |
Why?
|
| Conditioning, Operant | 5 | 2010 | 310 | 0.180 |
Why?
|
| Caudate Nucleus | 2 | 1996 | 390 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2020 | 28 | 0.170 |
Why?
|
| Tegmentum Mesencephali | 2 | 1999 | 59 | 0.170 |
Why?
|
| Thalamic Nuclei | 2 | 2019 | 111 | 0.170 |
Why?
|
| Apomorphine | 9 | 1999 | 149 | 0.170 |
Why?
|
| Choice Behavior | 1 | 2006 | 825 | 0.170 |
Why?
|
| Amygdala | 2 | 2006 | 1354 | 0.170 |
Why?
|
| Cocaine | 2 | 1995 | 958 | 0.160 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 3067 | 0.150 |
Why?
|
| Serotonin Receptor Agonists | 3 | 2005 | 151 | 0.150 |
Why?
|
| Metestrus | 1 | 2017 | 1 | 0.150 |
Why?
|
| Basal Ganglia | 2 | 2000 | 554 | 0.150 |
Why?
|
| Carbohydrates | 1 | 2020 | 390 | 0.150 |
Why?
|
| Male | 47 | 2023 | 360846 | 0.150 |
Why?
|
| Appetitive Behavior | 2 | 2008 | 39 | 0.150 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 18255 | 0.150 |
Why?
|
| Rats, Inbred BN | 2 | 2008 | 231 | 0.150 |
Why?
|
| Estrous Cycle | 1 | 2017 | 65 | 0.150 |
Why?
|
| Somatostatin | 1 | 2019 | 447 | 0.140 |
Why?
|
| Cognition | 3 | 2012 | 6992 | 0.140 |
Why?
|
| Quipazine | 1 | 1996 | 6 | 0.140 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2018 | 150 | 0.140 |
Why?
|
| Evoked Potentials, Visual | 1 | 2019 | 417 | 0.140 |
Why?
|
| Serotonin Antagonists | 2 | 1996 | 145 | 0.140 |
Why?
|
| Acoustic Stimulation | 2 | 2020 | 1235 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 1875 | 0.130 |
Why?
|
| Learning | 3 | 2017 | 1740 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 7 | 2023 | 22174 | 0.130 |
Why?
|
| Putamen | 1 | 1996 | 292 | 0.120 |
Why?
|
| Receptors, Adrenergic | 1 | 2015 | 155 | 0.120 |
Why?
|
| Kindling, Neurologic | 1 | 1994 | 24 | 0.120 |
Why?
|
| Mice | 15 | 2023 | 81539 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2002 | 1541 | 0.120 |
Why?
|
| Circadian Rhythm | 3 | 2019 | 2576 | 0.110 |
Why?
|
| Neuropeptides | 3 | 2006 | 944 | 0.110 |
Why?
|
| Anxiety | 1 | 2008 | 4573 | 0.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1996 | 489 | 0.110 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2012 | 14 | 0.100 |
Why?
|
| Fluoxetine | 1 | 1996 | 733 | 0.100 |
Why?
|
| Cerebral Cortex | 3 | 2019 | 5779 | 0.100 |
Why?
|
| Inflammasomes | 1 | 2017 | 526 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.100 |
Why?
|
| Mesencephalon | 7 | 1993 | 332 | 0.090 |
Why?
|
| Receptors, Dopamine | 3 | 1999 | 296 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2012 | 8601 | 0.090 |
Why?
|
| Physical Stimulation | 2 | 2009 | 517 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 602 | 0.090 |
Why?
|
| Eating | 2 | 2010 | 1539 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 426 | 0.090 |
Why?
|
| Eye Movements | 3 | 2008 | 511 | 0.090 |
Why?
|
| Methyltransferases | 1 | 2012 | 377 | 0.080 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2009 | 110 | 0.080 |
Why?
|
| Theophylline | 1 | 2008 | 131 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 999 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1171 | 0.080 |
Why?
|
| Acetylcholine | 2 | 2022 | 629 | 0.080 |
Why?
|
| Pons | 3 | 1999 | 240 | 0.070 |
Why?
|
| Presenilin-1 | 1 | 2012 | 660 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2011 | 7054 | 0.070 |
Why?
|
| Plaque, Amyloid | 1 | 2012 | 760 | 0.070 |
Why?
|
| Benzamides | 1 | 1993 | 1371 | 0.070 |
Why?
|
| Pyramidal Cells | 1 | 2009 | 369 | 0.070 |
Why?
|
| Reversal Learning | 1 | 2007 | 57 | 0.070 |
Why?
|
| Electrodes, Implanted | 3 | 2020 | 840 | 0.070 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 1111 | 0.070 |
Why?
|
| Septal Nuclei | 2 | 1987 | 85 | 0.070 |
Why?
|
| Cell Count | 2 | 2009 | 1835 | 0.070 |
Why?
|
| Dimethylphenylpiperazinium Iodide | 1 | 2005 | 6 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 1996 | 2220 | 0.070 |
Why?
|
| Locomotion | 1 | 2008 | 388 | 0.060 |
Why?
|
| Amphetamine | 5 | 1999 | 224 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2007 | 6228 | 0.060 |
Why?
|
| Color Perception | 1 | 2007 | 213 | 0.060 |
Why?
|
| Homeostasis | 1 | 2017 | 3323 | 0.060 |
Why?
|
| Random Allocation | 1 | 2010 | 2395 | 0.060 |
Why?
|
| Corpus Striatum | 3 | 1989 | 1235 | 0.060 |
Why?
|
| Triazoles | 2 | 2021 | 903 | 0.060 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 1995 | 63 | 0.060 |
Why?
|
| Homovanillic Acid | 2 | 1995 | 75 | 0.060 |
Why?
|
| Smell | 1 | 2007 | 259 | 0.060 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 699 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 9542 | 0.060 |
Why?
|
| Auditory Perception | 3 | 1986 | 583 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2006 | 2872 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2009 | 4125 | 0.050 |
Why?
|
| Nicotinic Agonists | 1 | 2005 | 265 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2014 | 12794 | 0.050 |
Why?
|
| Self Stimulation | 1 | 1982 | 47 | 0.050 |
Why?
|
| Satiation | 1 | 1983 | 83 | 0.050 |
Why?
|
| Electrophoresis, Capillary | 1 | 2002 | 63 | 0.050 |
Why?
|
| Biogenic Monoamines | 1 | 2002 | 50 | 0.050 |
Why?
|
| Ventromedial Hypothalamic Nucleus | 1 | 2002 | 46 | 0.050 |
Why?
|
| Galanin | 1 | 2002 | 42 | 0.050 |
Why?
|
| Piperidines | 2 | 2021 | 1656 | 0.050 |
Why?
|
| Periaqueductal Gray | 1 | 2002 | 110 | 0.050 |
Why?
|
| Body Weight | 2 | 2010 | 4618 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2010 | 975 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2015 | 9319 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 1987 | 795 | 0.050 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2001 | 24 | 0.050 |
Why?
|
| Motion Perception | 1 | 1985 | 374 | 0.050 |
Why?
|
| Hydroxyindoleacetic Acid | 4 | 1995 | 93 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2008 | 1403 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2002 | 1141 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 506 | 0.050 |
Why?
|
| Nicotine | 1 | 2005 | 680 | 0.040 |
Why?
|
| Animal Feed | 1 | 2020 | 112 | 0.040 |
Why?
|
| Neural Inhibition | 2 | 2003 | 590 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2009 | 11076 | 0.040 |
Why?
|
| Enkephalins | 2 | 1994 | 139 | 0.040 |
Why?
|
| Dopamine Agonists | 3 | 1998 | 352 | 0.040 |
Why?
|
| Stereotyped Behavior | 3 | 1993 | 135 | 0.040 |
Why?
|
| Exercise Test | 1 | 2007 | 2127 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15843 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14417 | 0.040 |
Why?
|
| Mammals | 1 | 2004 | 1132 | 0.040 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cholinergic Fibers | 2 | 1988 | 69 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 3839 | 0.040 |
Why?
|
| Cataplexy | 1 | 1999 | 61 | 0.040 |
Why?
|
| Motor Cortex | 1 | 2006 | 1007 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2018 | 67 | 0.040 |
Why?
|
| Proestrus | 1 | 2017 | 14 | 0.040 |
Why?
|
| Dialysis | 3 | 1993 | 73 | 0.040 |
Why?
|
| Receptors, Neuropeptide | 1 | 1999 | 106 | 0.040 |
Why?
|
| Oxidopamine | 5 | 1998 | 172 | 0.040 |
Why?
|
| Electric Stimulation | 4 | 1994 | 1736 | 0.040 |
Why?
|
| Oxygen | 1 | 2009 | 4227 | 0.040 |
Why?
|
| Receptors, Glutamate | 1 | 2018 | 228 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 5799 | 0.040 |
Why?
|
| alpha-Methyltyrosine | 1 | 1996 | 6 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 307 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 461 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 448 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2018 | 927 | 0.030 |
Why?
|
| Biological Assay | 1 | 2019 | 626 | 0.030 |
Why?
|
| Apoptosis | 1 | 2012 | 9490 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1996 | 208 | 0.030 |
Why?
|
| Substantia Innominata | 1 | 2015 | 23 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2015 | 128 | 0.030 |
Why?
|
| Autoradiography | 1 | 2015 | 728 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2006 | 10766 | 0.030 |
Why?
|
| Humans | 15 | 2020 | 761596 | 0.030 |
Why?
|
| Age Factors | 1 | 2010 | 18399 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 1995 | 1157 | 0.030 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 2 | 2005 | 32 | 0.030 |
Why?
|
| Neural Pathways | 3 | 2012 | 3060 | 0.030 |
Why?
|
| Action Potentials | 3 | 2009 | 1834 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2018 | 1176 | 0.030 |
Why?
|
| Blinking | 1 | 1993 | 133 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 837 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2005 | 4937 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2018 | 1989 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 903 | 0.020 |
Why?
|
| Models, Animal | 1 | 2018 | 2112 | 0.020 |
Why?
|
| Movement | 1 | 1999 | 1478 | 0.020 |
Why?
|
| Frontal Lobe | 2 | 1988 | 1420 | 0.020 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2015 | 530 | 0.020 |
Why?
|
| Hydroxydopamines | 3 | 1989 | 59 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 1179 | 0.020 |
Why?
|
| Morphine | 1 | 1995 | 657 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1994 | 1132 | 0.020 |
Why?
|
| Electrophysiology | 3 | 2004 | 1262 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 39106 | 0.020 |
Why?
|
| Synaptic Membranes | 1 | 2009 | 89 | 0.020 |
Why?
|
| Brain Stem | 2 | 1986 | 858 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 2 | 1993 | 147 | 0.020 |
Why?
|
| Data Collection | 1 | 2019 | 3322 | 0.020 |
Why?
|
| Parkinson Disease | 3 | 1989 | 2877 | 0.020 |
Why?
|
| Synaptic Transmission | 2 | 1987 | 1173 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1989 | 216 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 1115 | 0.020 |
Why?
|
| Indoles | 1 | 1996 | 1833 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1983 | 6391 | 0.020 |
Why?
|
| Nomifensine | 1 | 1987 | 14 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2008 | 161 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 30053 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 14665 | 0.020 |
Why?
|
| Astrocytes | 1 | 1994 | 1346 | 0.020 |
Why?
|
| Transfection | 1 | 1994 | 5774 | 0.020 |
Why?
|
| Female | 19 | 2020 | 392705 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2009 | 1090 | 0.020 |
Why?
|
| Reticular Formation | 1 | 1986 | 59 | 0.020 |
Why?
|
| Amphetamines | 1 | 1987 | 143 | 0.020 |
Why?
|
| Transplantation, Heterologous | 3 | 1989 | 2386 | 0.020 |
Why?
|
| Receptors, Presynaptic | 1 | 2005 | 15 | 0.020 |
Why?
|
| Food Deprivation | 1 | 1985 | 114 | 0.020 |
Why?
|
| Vocalization, Animal | 1 | 1985 | 94 | 0.020 |
Why?
|
| Nicotinic Antagonists | 1 | 2005 | 94 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 1998 | 297 | 0.020 |
Why?
|
| Body Temperature | 1 | 2008 | 781 | 0.020 |
Why?
|
| 5,7-Dihydroxytryptamine | 3 | 1989 | 13 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1985 | 405 | 0.020 |
Why?
|
| Movement Disorders | 1 | 1988 | 459 | 0.010 |
Why?
|
| Touch | 1 | 1985 | 313 | 0.010 |
Why?
|
| Evoked Potentials | 3 | 1986 | 1047 | 0.010 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2003 | 13 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1994 | 5790 | 0.010 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2003 | 27 | 0.010 |
Why?
|
| Amino Acids | 1 | 1989 | 1718 | 0.010 |
Why?
|
| Thalamus | 1 | 1989 | 1047 | 0.010 |
Why?
|
| Citalopram | 1 | 2005 | 402 | 0.010 |
Why?
|
| Perfusion | 1 | 1987 | 1373 | 0.010 |
Why?
|
| Vision, Ocular | 1 | 1985 | 455 | 0.010 |
Why?
|
| Receptors, Nicotinic | 1 | 2005 | 495 | 0.010 |
Why?
|
| Enkephalin, Methionine | 1 | 1981 | 26 | 0.010 |
Why?
|
| Aotidae | 1 | 2002 | 59 | 0.010 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 1982 | 108 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1985 | 785 | 0.010 |
Why?
|
| Diet | 1 | 2020 | 8075 | 0.010 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2002 | 43 | 0.010 |
Why?
|
| Endorphins | 1 | 1981 | 74 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 3847 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2017 | 23447 | 0.010 |
Why?
|
| Seizures | 1 | 1994 | 2957 | 0.010 |
Why?
|
| Hunger | 1 | 1983 | 206 | 0.010 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2000 | 39 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2000 | 45 | 0.010 |
Why?
|
| Naloxone | 2 | 1981 | 370 | 0.010 |
Why?
|
| Chlordiazepoxide | 1 | 1980 | 42 | 0.010 |
Why?
|
| Graft Survival | 5 | 1988 | 3820 | 0.010 |
Why?
|
| Globus Pallidus | 1 | 1981 | 250 | 0.010 |
Why?
|
| Emotions | 1 | 2012 | 2739 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1987 | 2645 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1993 | 370 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 1988 | 1436 | 0.010 |
Why?
|
| Organ Size | 1 | 2004 | 2254 | 0.010 |
Why?
|
| Perception | 1 | 1986 | 1197 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 4415 | 0.010 |
Why?
|
| Rotation | 2 | 1993 | 517 | 0.010 |
Why?
|
| Muscles | 1 | 1983 | 1576 | 0.010 |
Why?
|
| Proteomics | 1 | 2012 | 3848 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 14033 | 0.010 |
Why?
|
| Photoperiod | 1 | 1999 | 139 | 0.010 |
Why?
|
| Thioinosine | 1 | 1997 | 4 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2004 | 1336 | 0.010 |
Why?
|
| Heart Rate | 1 | 2008 | 4195 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20100 | 0.010 |
Why?
|
| Fetus | 3 | 1989 | 1863 | 0.010 |
Why?
|
| Genomics | 1 | 2012 | 5821 | 0.010 |
Why?
|
| Reinforcement Schedule | 1 | 1996 | 123 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2002 | 2329 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 1996 | 288 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 16592 | 0.010 |
Why?
|
| Haloperidol | 1 | 1996 | 389 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1999 | 999 | 0.010 |
Why?
|
| Video Recording | 1 | 1999 | 967 | 0.010 |
Why?
|
| Ethanol | 1 | 1980 | 1324 | 0.010 |
Why?
|
| Brain Mapping | 2 | 1986 | 6635 | 0.010 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1993 | 122 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2000 | 2490 | 0.010 |
Why?
|
| Reference Values | 2 | 1989 | 4920 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1999 | 1436 | 0.010 |
Why?
|
| Trigeminal Nerve | 1 | 1993 | 248 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 1999 | 1252 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12059 | 0.010 |
Why?
|
| Pain | 1 | 1985 | 5073 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17904 | 0.010 |
Why?
|
| Cell Division | 2 | 1988 | 4465 | 0.010 |
Why?
|
| Kynurenic Acid | 1 | 1989 | 44 | 0.010 |
Why?
|
| Bicuculline | 1 | 1989 | 96 | 0.010 |
Why?
|
| Aging | 1 | 1988 | 8710 | 0.000 |
Why?
|
| Denervation | 1 | 1989 | 265 | 0.000 |
Why?
|
| Acetylcholinesterase | 1 | 1988 | 156 | 0.000 |
Why?
|
| Injections, Intraventricular | 1 | 1988 | 225 | 0.000 |
Why?
|
| Kinetics | 1 | 1996 | 6374 | 0.000 |
Why?
|
| Catecholamines | 1 | 1988 | 386 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1994 | 18966 | 0.000 |
Why?
|
| Cerebral Ventricles | 1 | 1988 | 542 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1987 | 698 | 0.000 |
Why?
|
| Mephenesin | 1 | 1983 | 1 | 0.000 |
Why?
|
| Muscle Tonus | 1 | 1983 | 82 | 0.000 |
Why?
|
| Carbachol | 1 | 1983 | 223 | 0.000 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 1981 | 9 | 0.000 |
Why?
|
| Flupenthixol | 1 | 1981 | 11 | 0.000 |
Why?
|
| Auditory Pathways | 1 | 1983 | 237 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2000 | 12130 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1987 | 2257 | 0.000 |
Why?
|
| Antibodies | 1 | 1988 | 2418 | 0.000 |
Why?
|
| Gestational Age | 1 | 1988 | 3577 | 0.000 |
Why?
|
| Swine | 1 | 1989 | 5915 | 0.000 |
Why?
|
| Cell Survival | 1 | 1988 | 5791 | 0.000 |
Why?
|
| Visual Perception | 1 | 1986 | 1389 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1981 | 1968 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 11904 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1989 | 4446 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1980 | 1416 | 0.000 |
Why?
|
| Adult | 1 | 2002 | 221210 | 0.000 |
Why?
|